Ballentine Partners, LLC Bristol Myers Squibb CO Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q3 2024
A detailed history of Ballentine Partners, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ballentine Partners, LLC holds 39,045 shares of BMY stock, worth $2.25 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
39,045
Previous 35,646
9.54%
Holding current value
$2.25 Million
Previous $1.48 Million
36.49%
% of portfolio
0.03%
Previous 0.03%
Shares
29 transactions
Others Institutions Holding BMY
# of Institutions
2,536Shares Held
1.47BCall Options Held
31.6MPut Options Held
35M-
Vanguard Group Inc Valley Forge, PA189MShares$10.9 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY159MShares$9.15 Billion0.15% of portfolio
-
State Street Corp Boston, MA92.9MShares$5.36 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY77.9MShares$4.5 Billion0.33% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA61MShares$3.52 Billion0.61% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $123B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...